Lv3
270 积分 2026-05-12 加入
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
1个月前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1个月前
已完结
Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”
2个月前
已完结
Methods for non-proportional hazards in clinical trials: A systematic review
2个月前
已完结
Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia
3个月前
已关闭
A Practical Review of Adaptive Platform Trials
3个月前
已关闭
Introduction to Adaptive Trial Designs and Master Protocols
3个月前
已完结
Introduction to Adaptive Trial Designs and Master Protocols
3个月前
已关闭
皖公网安备34019202002308
